Search

541 Result(s)
Sort by

clinical_collaboration_with_Mirati

clinical_collaboration_with_Mirati

Boehringer Ingelheim and Mirati are teaming up in a clinical collaboration to evaluate the combination of the SOS1::pan-KRAS and the selective G12C inhibitor.
Matthias Muenks

Matthias Muenks

Matthias Muenks, Global Engineering Process and Data Manager, speaks about our innovation and culture.
Fast-Track-Designation-NASH

Fast-Track-Designation-NASH

Boehringer Ingelheim and Zealand Pharma announced that the FDA granted Fast Track Designation to the dual agonist BI 456906 for adults with NASH.
InPedILD_trial_enrollment

InPedILD_trial_enrollment

First patient enrolled in InPedILD™, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and adolescents
BI_PharmAccess_launch_digital_healthcare_program

BI_PharmAccess_launch_digital_healthcare_program

Boehringer Ingelheim and PharmAccess launch a new mobile support program „Tiba Yako“ to empower patients to become more aware, access care and take charge of their disease management
university-of-medical-excellence-harvard

university-of-medical-excellence-harvard

A program designed by Harvard Medical School Executive Education with the goal of accelerating clinical development and medical affairs
Really Digital, Mr Hach!

Really Digital, Mr Hach!

The Head of User Experience and SCRUM at Boehringer Ingelheim’s digital lab BI X offers a glimpse into his work and motivation.
EFPIA disclosure

EFPIA disclosure

Disclosure of Boehringer Ingelheim affiliates in countries with EFPIA member associations.
The status of schizophrenia care

The status of schizophrenia care

A closer look at the status of the schizophrenia care landscape, an often misunderstood mental health condition
Listen to the sounds disrupting farms worldwide

Listen to the sounds disrupting farms worldwide

A pioneer in Precision Livestock Farming, Prof. Daniel Berckmans reveals how online monitoring technology is bringing healthier pigs closer to farmers and consumers
Boehringer Ingelheim Access to Healthcare Strategy 2025

Boehringer Ingelheim Access to Healthcare Strategy 2025

Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering more health to humans, animals and communities around the world. Read more about our holistic approach.
Living Independence

Living Independence

Boehringer Ingelheim’s corporate culture is based on values that have been applied since the company was founded in 1885.
Innovation from within

Innovation from within

Justine Rochon and Marc Weimer talk about the transformation of Biostatistics and Data Sciences (BDS) into a modern organisation in drug development.